Summary, Twenty-six Type1 diabetic patients previously treated for 10-20 months with twice daily conventional bovine isophane insulin (containing at least 1000 ppm proinsulin) were changed to highly purified (< 1 ppm proinsulin) bovine isophane for 6 months (Switch group). Insulin antibody levels fell significantly from a geometric mean of 14.9 to 9.1 l-tg/1. Thirty-two patients with newly diagnosed Type 1 diabetes were treated with the same highly purified bovine isophane insulin twice daily for 6 months (Starter group). Their insulin antibody levels rose from a geometric mean of 1.9 to 8.2 ~tg/1 in contrast to values of 1.4 rising to 16.3 ~tg/1 in an age and sex matched historical control group treated from diagnosis only with twice daily conventional bovine isophane insulin. Lipoatrophy at injection sites developed in three (9%) in the Starter group treated with highly purified bovine isophane compared to 7 (22%) of those on conventional bovine isophane. Insulin dose and diabetic control did not differ between the groups. Starter and Switch groups were subsequently treated with semi-synthetic human isophane insulin for 6 months during which insulin antibody levels fell significantly from a geometric mean of 8.5 to 4.4 ~tg/1 (p< 0.001). We conclude that bovine insulin purified to less than 1 ppm proinsulin is significantly less immunogenic than its conventional proinsulin contaminated counterpart but even at this level of purity is still more immunogenic than human insulin of equivalent purity.
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Previous studies [1] [2] [3] have shown that bovine insulin purified by sequential recrystallisation to > 1000ppm proinsulin (conventional bovine insulin) is much more immunogenic that its highly purified ( < 1 ppm proinsulin) porcine counterpart. Not only are levels of insulin antibody higher but antibodies to C-peptide and other islet proteins are often present after using the conventional preparation [3] [4] [5] [6] . We previously studied patients on conventional bovine soluble and isophane insulins who were transferred to equivalent bovine preparations purified to a proinsulin content of 20-40 ppm [7] . This significantly reduced antibodies reactive with C peptide but did not change insulin antibody levels. It left open the question of whether bovine insulin is inherently more immunogenic than pork or human because the "purified" bovine still contained significantly more proinsulin than the porcine with which it was compared. In the present study we have examined the immunogenicity of highly purified bovine isophane insulin (containing < 1 ppm proinsulin) and compared it with a conventional bovine isophane and semi-synthetic human isophane insulin.
Patients

Switch group
Twenty-six patients with Type 1 diabetes were treated from diagnosis 10-20 months earlier with twice daily conventional bovine (CB) isophane insulin only. They and the other patients reported in this paper had all been started on insulin as outpatients and had never received soluble insulin. These 26 were then switched to highly purified bovine isophane insulin (HPB) for 6 months followed by semi-synthetic human isophane (SSH) for a further 6 months. Half the group were men with a mean age of 39years (range 19-72) compared to 38years (range 15-67) for the women.
Starter group
Thirty-two newly diagnosed insulin-requiring patients, part of a series of 100 reported els-where [8] , received highly purified bovine isophane insulin (HPB) twice daily for the first 6 months after diagnosis followed by semi-synthetic human isophane (SSH) twice daily for a further 6 months. There were 22 men of mean age 28 years (range 11-67) and 10 women (mean age 26 years: range 19-70). All had acute onset Type 1 diabetes except a 70-year-old woman who needed insulin treatment because of hyperglycaemia and weight loss uncontrolled by maximum doses of oral hypoglycaemic agents. The 26 patients had been treated exclusively with bovine isophane prior to entry at month 0. They then received highly purified bovine insulin for 6 months (0 to 6 a) followed by highly purified human insulin for a further 6 months (6b to 12) Fig.2 . IgG insulin binding (bovine ligand) in the Starter group. The 32 patients had newly diagnosed diabetes and were treated with highly purified bovine insulin for 6 months (0 to 6a) followed by highly purified human insulin for a further 6 months (6b to 12) To compare the effects of HPB isophane insulin with a conventional bovine preparation, we chose patients from another study performed by us [9] in which treatment was exclusively with twice daily CB from diagnosis. Matching was done blind from a pool of 120 patients who were matched for sex, diabetes type and age to within 5 years.
All patients with Type 1 diabetes fulfilled the following criteria at diagnosis: ketonuria of 3.9 mmol/l or greater ("moderate" or "large" with ketostix: Ames Company Ltd., Elkhardt, Indiana, USA) and/or two of the following: (a) acute onset of symptoms (present less than 1 month); (b) body mass index (BMI) of less than 24 kg/m 2 or marked weight loss; (c) severe symptoms; (d) a first degree relative on insulin. These indices have been examined in relation to presence of islet cell antibodies and possession of HLA DR3 and/or DR4 and have been shown to be valid diagnostic criteria for Type 1 diabetes [8] . No patient in any of the three groups had diabetic complications, none was on any drug treatment and none had any serious incidental disease.
Materials and methods
The conventional bovine isophane insulins used in this study were obtained from Evans Medical Ltd. (Beaconsfield, UK) and Weddel Pharmaceuticals Ltd. (London, UK) and contained at least 1000 ppm proinsulin. Highly purified "monocomponenr' bovine isophane and semi-synthetic human isophane (Protaphane Human) were supplied by Novo Industries, Copenhagen and contained < 1 ppm proinsulin. All patients were seen by a single doctor (RMW) and their insulin preparations carefully checked. None was admitted to hospital during the study and we are as certain as it is possible to be that they did not receive any other insulin preparation. IgG insulin antibody reactive with 125I-labelled bovine or human insulin was measured as described previously [6] . Insulin was removed from sera before assay and results expressed in gg/l without subtraction of a value for normal serum binding [6] . Haemoglobin A1 (HbA0 was measured by electroendosmosis (Coming Medical and Scientific, Medfield, Mass, USA) [10] . The normal range (mean_+ 2 SD in non-diabetic patients) in our laboratory is 5-10% [11] .
Statistical methods
Loge transformation of the insulin antibody results was used to normalise the distribution. Statistical analysis employed standard Student's t-test and its modification for paired differences. Figure 1 shows insulin antibody levels for the Switch group who, up to the point of entry in the present study (month 0), had been treated exclusively with twice daily CB isophane insulin for between 10 and 20 months. After changing to HPB isophane insulin (months 0-6 a) insulin antibody levels fell from a geometric mean of 14.9 to 9.1 l~g/1 (p< 0.001). They were then treated with SSH isophane insulin for a further 6 months (months 6b-12). Two were on HPB for longer than 6months before transfer to SSH and it is for this reason that data for the After 6 months' treatment with HPB isophane insulin, antibody levels did not differ significantly between the Starterand the Switch groups (8.2 vs 9.1 gg/1 respectively) indicating that previous treatment with CB isophane insulin does not influence final levels of antibody 6 months after transfer to HPB insulin.
Results
Insulin antibody levels
For the purposes of illustration Table2 shows pooled data for the SSH insulin treatment period for both the Switch and Starter groups. IgG antibody binding to both labelled bovine and human ligands fell significantly during this period (p< 0.001). end of the first 6 months treatment and the beginning of the second 6 month period have been separated into two columns (6 a and 6 b) although there is no significant difference between the means of the two. A fuKher significant fall in insulin antibody levels occurred during treatment with SSH (months 6b-12) from 9.1 to 4.6 p~g/1 (p< 0.001).
Insulin dose and diabetic control
The Starter group (Fig.2) were treated with HPB isophane insulin from diagnosis (months 0-6a) and then transferred to SSH isophane for a second period of six months (months 6b-12). For the first 6 months after diagnosis, while on HPB, insulin antibody levels rose to a geometric mean of 8.1 ~g/1 compared to 16.3 ~tg/1 in the matched control group who received conventional bovine isophane for the first 6 months of treatment (p< 0.001 ; Table 1 ). Antibody levels fell significantly during the second treatment period in the Starter group (Fig. 2 ) from 8.0 to 4.2 p~g/1 (p< 0.001). Nine patients were treated with HPB for more than 6 months so that nine points differ between months 6 a and 6 b. However, there is no significant difference between geometric means for these two groups.
Another indication of the greater immunogenicity of CB insulin is that after at least 6 months on CB only two (7%) patients in the Switch group had insulin antibody levels within the range of normal serum binding ( < 5 p~g/1) whereas 10 (30%) of the Starter group were still within this range of binding after 6 months on HPB. Lipoatrophy at injection sites developed in seven (22%) of those treated with CB isophane compared to only three (9%) in the Starter group treated with HPB.
This study was not specifically designed to examine the effects of insulin antibodies on insulin dose and diabetic control but doses and HbAl levels were similar after six months treatment with CB or HPB insulin. Patients treated with CB isophane insulin twice daily took 0.42+0.19 (SD) U/kg/day compared with 0.39+ 0.16 U/kg per day for those treated with HPB (p> 0.1). Mean HbA1 in patients receiving CB was 11.4+2.2% compared with 10.4+_3.5% for those treated with HPB (p>0.1). No elective reduction in dose was made on changing to human insulin. Mean HbA1 concentration rose slightly but not significantly (p>0.1) in both groups during treatment with human insulin, from 10.9 +_ 3.5 to 11.5 +_2.9% in the Starter group and from 10.0 +_ 2.9 to 10.6 +_ 3.1% in the Switch group.
Discussion
Previous studies have shown that changing from conventional bovine to highly purified porcine insulin (i. e. a change in both species and purity) reduces levels of insulin antibody and antibodies reactive with other pancreatic peptides and hormones [2, 3, 7, 12] . However, we [7] found that a reduction in proinsulin contamination of bovine insulin to 20-40 ppm did not lower antibody levels in patients previously "immunised" with a conventional bovine preparation. The availability of bovine insulin purified to < 1 ppm proinsulin has allowed us to examine the intrinsic immunogenicity of bovine insulin. The present study shows that purifying bovine insulin to < 1 ppm proinsulin does reduce antibody levels in patients previously treated with CB insulin. Only two patients (7%) in the Switch group had antibody levels within the range of normal serum binding whereas ten (30%) in the Starter group were below this level after 6months treatment with HPB. This underscores the greater immunogenicity of conventional bovine insulin in relation to its highly purified counterpart. Howevel; HPB insulin is still significantly more immunogenic than human insulin of equivalent purity and formulation since the change to human insulin produced a further fall in insulin antibody levels in both Starter and Switch groups. This is in keeping with a previous study in which there was a significant fall in antibody level on transfer from highly purified beef to human ultralente insulin [13] . The three aminoacid residues by which beef differs from human insulin (AS, A10 and B30) are relatively close together on the surface of the bovine insulin molecule [14] and create sufficient alteration to induce an immune response greater than that seen with human insulin. As shown previously [6] , antibodies induced by bovine insulin cross react to a large extent with the human molecule and in this study levels of antibody binding to bovine and human insulin were reduced to a similar degree after transfer to the human preparation ( Table 2 ).
The relevance of insulin antibodies to the course of diabetes and its complications is disputed [15] . However, injection site lipoatrophy is thought to have an immunological basis and is common during treatment with conventional bovine insulin [16] but has been reported infrequently in patients receiving purified bovine [17] and highly purified porcine insulin [18] . It is therefore of interest that only three patients (9%) initially treated with highly purified bovine insulin developed lipoatrophy compared to seven (22%) after 6 months on conventional bovine isophane insulin. The condition improved in four of the latter during treatment with HPB and resolved in all within two months of starting human insulin. All patients with lipoatrophy had high levels of insulin antibody which fell on human insulin paripassu with resolution of the lipoatrophy.
